MMIT (Managed Markets Insight & Technology)’s Post

What data types do pharma companies need to get visibility into unmet needs and patient stratification? On April 10, join us for a webinar to answer all your questions about patient-level data analytics. Register for priority access to the webinar: https://ow.ly/OZTX50R28ki. #Pharma #PharmaceuticalCompanies #PharmaAnalytics #Webinar

Pharmaceutical companies can gain valuable insights into patient management by analyzing unstructured data such as pathology reports or physician notes. Register for priority access to our April 10 webinar to learn about the importance of unstructured data: https://ow.ly/CI2w50R7COM. #Pharma #PharmaceuticalCompanies #PharmaAnalytics #Physicians #Webinar

On April 10, MMIT’s market access experts will discuss what’s driving pharma companies to focus on patient-level data and analytics. We’ll address the specifics of tracking disease progression, clinical triggers, and more! Register for priority access to the webinar: https://ow.ly/hFyZ50R29qa. #Pharma #PharmaceuticalCompanies #PharmaAnalytics #PatientData #MarketAccess #Webinar

Join me on April 10 as I moderate this session with two of MMIT’s best discussing how real world, lab and payer data can help identify access hurdles and overcome them, smoothing patient access to therapies! Be there or be 🔲!

Our 2024 State of Patient Access Survey reveals that 73% of pharma companies leverage real-world data to enhance decision-making beyond market access. Discover the diverse applications of RWD 💡 📅 🚀 , from Phase I through competitor entry, in this insightful infographic: https://ow.ly/wIJA50StOlE. #PatientAccess #Pharma #RealWorldData

Pairing coverage data with claims data can give pharma commercial teams a unique view of payer and prescriber behavior—and help maximize patient access. Meet with an MMIT expert at Asembia's AXS24 Summit to find out how. https://ow.ly/QPgj50QWOhp #Asembia24 #MarketAccess #Pharma #LifeSciences Asembia

Are you going to Asembia's AXS24 Summit? Meet with MMIT’s experts to learn how real-world data can help you uncover insights into the patient journey. https://ow.ly/9jCe50QWOaR #Asembia24 #MarketAccess #Pharma #LifeSciences Asembia

A pharmaceutical manufacturer with a recently launched therapy needed a better understanding of how payers determined utilization management for expensive new treatments in the rare disease category. The manufacturer needed to understand which factors influence payers to cover a product’s off-label use, identify appropriate market access analogs for its therapy, and determine whether to seek a new FDA indication in rare diseases. MMIT’s Engage solution solves these challenges, which allows payer responses to be viewed in real-time. What happened next? Check out the full Use Case to find out: https://ow.ly/YpHY50QVCSk #Pharma #PharmaManufacturing #Payers #RareDiseases #MarketAccess #FDAIndication

When one pharmaceutical company debated whether to seek a new FDA indication, it turned to MMIT for fast-payer insights. Within the week, the company had the qualitative data it needed. Read the Use Case: https://ow.ly/a7nj50QVCNe. #Pharma #PharmaManufacturing #Payers #RareDiseases #MarketAccess #FDAIndication

A pharmaceutical manufacturer with a recently launched therapy needed a better understanding of how payers determined utilization management for expensive new treatments in the rare disease category. The manufacturer needed to understand which factors influence payers to cover a product’s off-label use, identify appropriate market access analogs for its therapy, and determine whether to seek a new FDA indication in rare diseases. MMIT’s Engage solution solves these challenges, which allows payer responses to be viewed in real-time. What happened next? Check out the full Use Case to find out: https://ow.ly/ix8Z50QVE5U #Pharma #PharmaManufacturing #Payers #RareDiseases #MarketAccess #FDAIndication